CannaPharmaRX Past Earnings Performance

Past criteria checks 2/6

CannaPharmaRX has been growing earnings at an average annual rate of 36.1%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 107% per year.

Key information

36.1%

Earnings growth rate

62.9%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate107.0%
Return on equityn/a
Net Margin408.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How CannaPharmaRX makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:CPMD Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240100
30 Jun 240100
31 Mar 240-710
31 Dec 230410
30 Sep 230-750
30 Jun 230-850
31 Mar 230-850
31 Dec 220-950
30 Sep 220-1220
30 Jun 220-1220
31 Mar 220-1230
31 Dec 210-930
30 Sep 210-1340
30 Jun 210-1550
31 Mar 210-1450
31 Dec 200-2050
30 Sep 200-1840
30 Jun 200-2430
31 Mar 200-2430
31 Dec 190-2030
30 Sep 190-1320
30 Jun 190-520
31 Mar 190-410
31 Dec 180-310
30 Sep 180-100
30 Jun 180000
31 Mar 180000
31 Dec 170000
30 Sep 170000
30 Jun 170000
31 Mar 170000
31 Dec 160-110
30 Sep 160-550
30 Jun 160-770
31 Mar 160-11110
31 Dec 150-12120
30 Sep 150-1190
30 Jun 150-1080
31 Mar 150-640

Quality Earnings: CPMD has a large one-off gain of $6.6M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: CPMD became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CPMD has become profitable over the past 5 years, growing earnings by 36.1% per year.

Accelerating Growth: CPMD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CPMD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: CPMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 03:52
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CannaPharmaRX, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution